What is GLP-1 Used For? Exploring the Benefits and Applications

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists are now approved across a wider range of conditions than most summaries acknowledge, and the list has grown quickly. Depending on the specific product, FDA-approved uses include glycemic control in type 2 diabetes, reduction of major adverse cardiovascular events, reduction of kidney disease progression, chronic weight management, obstructive sleep apnea in adults with obesity, and — under accelerated approval — noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. No single product carries all of them. Which uses apply depends entirely on which label you are reading, and that is the most practical thing to understand about this class.

The Mechanism in Plain Terms

Glucagon-like peptide-1 is an incretin hormone released from the gut in response to food. GLP-1 receptor agonists are engineered to act at that receptor with a much longer duration than the native hormone — semaglutide has an elimination half-life of approximately one week, which is what makes once-weekly dosing possible.

Receptor activation influences glucose-dependent insulin secretion, gastric emptying and appetite regulation. Because the insulin effect is glucose-dependent, these agents behave differently from insulin itself; the labels warn about hypoglycemia primarily in the context of concomitant insulin or insulin secretagogue use.

Type 2 Diabetes: The Original Approval

The Ozempic label covers three indications, all in adults with type 2 diabetes: improving glycemic control as an adjunct to diet and exercise, reducing the risk of major adverse cardiovascular events in those with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in those with chronic kidney disease.

The Rybelsus and Ozempic tablets label covers oral semaglutide for glycemic control and for reducing major adverse cardiovascular event risk in adults with type 2 diabetes at high risk for those events. Mounjaro (tirzepatide) is indicated as an adjunct to diet and exercise for glycemic control in type 2 diabetes and carries no weight-management indication.

Chronic Weight Management

The Wegovy label covers reducing excess body weight and maintaining weight reduction long term in adults and pediatric patients aged 12 and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity.

Zepbound (tirzepatide) is approved for chronic weight management and separately for moderate to severe obstructive sleep apnea in adults with obesity. Foundayo (orforglipron), approved April 1, 2026 under NDA 220934, is an oral GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity for the same weight-management population, with a labeled limitation against concomitant use with another GLP-1 receptor agonist.

Cardiovascular and Renal Outcomes

These are among the most consequential additions to the class. Wegovy injection is indicated to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal myocardial infarction or non-fatal stroke — in adults with established cardiovascular disease and either obesity or overweight. Wegovy tablets carry the same cardiovascular indication in adults.

On the renal side, Ozempic is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. These indications rest on dedicated outcomes trials, not on extrapolation from weight or glucose effects.

Liver Disease and Sleep Apnea

Wegovy injection carries an indication for noncirrhotic MASH with moderate to advanced liver fibrosis, consistent with stages F2 to F3, in adults. The label states that this indication is approved under accelerated approval based on improvement of MASH and fibrosis, and that continued approval may be contingent on verification in a confirmatory trial. Wegovy tablets do not carry this indication.

Zepbound's obstructive sleep apnea indication covers moderate to severe disease in adults with obesity. Both of these illustrate the same point: the class is not one drug with one use, and indication-level precision is what makes any of this actionable.

What This Means When Choosing

The right question is never "should I take a GLP-1." It is which condition is being treated, which product carries an indication for it, and whether that product is appropriate given your history and other medications. Labeled contraindications include a personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2.

Compounded semaglutide and tirzepatide are a distinct regulatory category, dispensed by licensed pharmacies against individual prescriptions and not reviewed by the FDA for safety, effectiveness or quality before marketing. They are not generics; no approved generic of any of these brands exists.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What conditions are GLP-1 medications approved to treat?

Depending on the specific product: glycemic control in type 2 diabetes, reduction of major adverse cardiovascular events, reduction of sustained eGFR decline and end-stage kidney disease, chronic weight management, moderate to severe obstructive sleep apnea in adults with obesity, and — under accelerated approval — noncirrhotic MASH with moderate to advanced fibrosis. No single product carries all of these indications.

How do GLP-1 receptor agonists work?

Glucagon-like peptide-1 is an incretin hormone released from the gut in response to food. These medications activate its receptor with a much longer duration than the native hormone; semaglutide has an elimination half-life of approximately one week. Receptor activation influences glucose-dependent insulin secretion, gastric emptying and appetite regulation. The insulin effect being glucose-dependent shapes the labels' hypoglycemia warnings.

Which GLP-1 products are approved for weight management?

Wegovy injection and Wegovy tablets, Zepbound, and Foundayo (orforglipron), approved April 1, 2026 under NDA 220934 as an oral tablet. Zepbound is additionally approved for moderate to severe obstructive sleep apnea in adults with obesity. Ozempic, Rybelsus, Ozempic tablets and Mounjaro are indicated for type 2 diabetes and carry no weight-management indication.

Do any of these treat liver disease?

Wegovy injection carries an indication for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis, consistent with stages F2 to F3, in adults. The label states this indication is approved under accelerated approval based on improvement of MASH and fibrosis, with continued approval potentially contingent on verification in a confirmatory trial. Wegovy tablets do not carry it.

Can two GLP-1 products be combined?

The labels say no. Wegovy states that concomitant use with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended. Zepbound states that coadministration with other tirzepatide-containing products or any GLP-1 receptor agonist is not recommended. Foundayo carries the same limitation against concomitant use with another GLP-1 receptor agonist.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.